Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop small molecules that can modulate RNA in a deal worth up to $1.8 billion. The upfront payment was not disclosed. The deal focuses on two rare neurological disease targets. Skyhawk is responsible for early research, and Ipsen is responsible for all development after candidate nomination.
top of page
bottom of page